{"id":473841,"date":"2021-04-08T16:10:17","date_gmt":"2021-04-08T20:10:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473841"},"modified":"2021-04-08T16:10:17","modified_gmt":"2021-04-08T20:10:17","slug":"personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/","title":{"rendered":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae"},"content":{"rendered":"

<\/p>\n

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae<\/b><\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE<\/a>)–
\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021.\n<\/p>\n

\nThese abstracts showcase data from ImmunoID NeXT<\/a>, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.\n<\/p>\n

\nFollowing are details and links to the scientific posters that will be presented at the online meeting.\n<\/p>\n\n\n\n\n\n\n\n
\n

Poster Number, Session Category and Session Title<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

Title & Presenter<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

Date<\/b><\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n

Location<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

399<\/b><\/p>\n

\nClinical Research (Excluding Trials)\n<\/p>\n

\n\u00a0\n<\/p>\n

\nBiomarkers Predictive of Therapeutic Benefit\n<\/p>\n<\/td>\n

\n

Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm <\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nPresenter: Rachel Marty Pyke, PhD\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nApril 10, 2021\n<\/p>\n<\/td>\n

\n

Online<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

555<\/b><\/p>\n

\nClinical Research (Excluding Trials)\n<\/p>\n

\n\u00a0\n<\/p>\n

\nLiquid Biopsies: Circulating DNA\n<\/p>\n<\/td>\n

\n

Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy<\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nPresenter: Charles Abbott, PhD\n<\/p>\n<\/td>\n

\n

\nApril 10, 2021\n<\/p>\n<\/td>\n

\n

Online<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

1898<\/b><\/p>\n

\nImmunology
\n
Tumor\n<\/p>\n

\n\u00a0\n<\/p>\n

\nAntigenicity\/Processing and Presentation\n<\/p>\n<\/td>\n

\n

Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework <\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nPresenter: Rachel Marty Pyke, PhD\n<\/p>\n<\/td>\n

\n

\nApril 10, 2021\n<\/p>\n<\/td>\n

\n

Online<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

2227<\/b><\/p>\n

\nMolecular and Cellular Biology \/ Genetics\n<\/p>\n

\n\u00a0\n<\/p>\n

\nGenomic Profiling of Tumors\n<\/p>\n<\/td>\n

\n

Pan-cancer shedding patterns of tumor circulating cell free DNA <\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nPresenter: F\u00e1bio Navarro, PhD\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nApril 10, 2021\n<\/p>\n<\/td>\n

\n

Online<\/a><\/p>\n<\/td>\n<\/tr>\n

\n

2241<\/b><\/p>\n

\nMolecular and Cellular Biology \/ Genetics\n<\/p>\n

\n\u00a0\n<\/p>\n

\nGenomic Profiling of Tumors\n<\/p>\n<\/td>\n

\n

Profiling tumor-infiltrating immune cells using an augmented transcriptome <\/b><\/p>\n

\n\u00a0\n<\/p>\n

\nPresenter: Eric Levy, PhD\n<\/p>\n<\/td>\n

\n

\nApril 10, 2021\n<\/p>\n<\/td>\n

\n

Online<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n

About Personalis, Inc.<\/b><\/p>\n

\nPersonalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency, and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient\u2019s cancer and immune response. The Personalis NeXT Platform<\/a> is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory<\/a> is GxP aligned as well as CLIA\u201988-certified and CAP-accredited. For more information, please visit www.personalis.com<\/a> and follow Personalis on Twitter (@PersonalisInc<\/a>).\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nAll statements in this press release that are not historical are \u201cforward-looking statements\u201d within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis\u2019 business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis\u2019 filings with the U.S. Securities and Exchange Commission, including Personalis\u2019 most recent reports on Forms 8-K, 10-K and 10-Q, the company\u2019s registration statement on Form S-3 filed on December 30, 2020, and the company\u2019s prospectus supplement filed on January 27, 2021, and include those listed under the caption \u201cRisk Factors.\u201d Personalis disclaims any obligation to update such forward-looking statements.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210408005927\/en\/<\/a><\/span><\/p>\n

Investor Relations Contact for Personalis:
\n<\/b>
Caroline Corner
\n
investors@personalis.com
\n<\/a>
415-202-5678\n<\/p>\n

Media Contact for Personalis:
\n<\/b>
Jennifer Havlek
\n
pr@personalis.com
\n<\/a>
www.personalis.com
\n<\/a>
650-752-1300\n<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae MENLO PARK, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021. These abstracts showcase data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing … <\/p>\n

Continue reading “Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473841","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPersonalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae MENLO PARK, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021. These abstracts showcase data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing … Continue reading "Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T20:10:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae\",\"datePublished\":\"2021-04-08T20:10:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/\"},\"wordCount\":659,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/\",\"name\":\"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-08T20:10:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/","og_locale":"en_US","og_type":"article","og_title":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk","og_description":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae MENLO PARK, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present new data in scientific posters to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held online, April 10-15, 2021 and May 17-21, 2021. These abstracts showcase data from ImmunoID NeXT, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing … Continue reading \"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T20:10:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae","datePublished":"2021-04-08T20:10:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/"},"wordCount":659,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/","name":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-08T20:10:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005927r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-presents-data-at-aacr-annual-meeting-2021-showcasing-the-personalis-immunoid-next-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473841"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}